Drugs / HSY244
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04582409 | Nov 2020 → Jul 2022 | atrial fibrillation | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSY244 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04582409 ↗ |
| Route | Intravenous | “via intravenous infusion” NCT04582409 ↗ |